## Drug Summary
Thioguanosine triphosphate (thio-GTP) is not a drug but rather a biochemical analogue of guanosine triphosphate (GTP) that features a sulfur atom replacing an oxygen atom in the sugar moiety. It is primarily used in research settings to study various biological processes, including the regulation of GTPases and the synthesis of guanine nucleotides. Functionally, thio-GTP is involved in several biochemical reactions where it may act as a substitute for GTP, often used to assess the mechanism and kinetics of GTP-binding proteins, given its ability to selectively bind and sometimes inhibit these proteins due to its altered chemical structure.

## Drug Targets, Enzymes, Transporters, and Carriers
Since thioguanosine triphosphate itself is not conventionally categorized as a therapeutic drug, specific targets, enzymes, transporters, and carriers directly associated with its action in a therapeutic context are generally not defined. In biochemical studies, however, it is used to probe the function of various GTPases, which play critical roles in cell signaling and metabolism. These studies help elucidate the interactions and dynamics of thioguanosine triphosphate with these important cellular proteins.

## Pharmacogenetics
The pharmacogenetic aspects of thioguanosine triphosphate are inherently limited due to its status as a research tool rather than a therapeutic drug. In genetic studies, any observed variations in response to thio-GTP are more likely to reflect genetic differences affecting the GTPases or other interacting proteins rather than thio-GTP itself. However, insights into how genetic variations in those proteins might affect their interaction with naturally occurring analogues like GTP could be extrapolated to understand their potential interactions with thio-GTP in research contexts. This provides a basis for understanding pharmacogenetic implications in broader scenarios involving similar nucleotide analogues used in therapies, such as antiviral or anticancer treatments.